Overview
KURA market data
Price History
KURA price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for KURA. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Kura Oncology To Feature Updated Phase 1a Results From Ongoing FIT-001 Phase 1a/1b Clinical Trial Evaluating Darlifarnib In Combination With Cabozantinib In Advanced Renal Cell Carcinoma In Oral Presentation At 2026 KCRSBenzinga · Jul 14, 2026, 11:21 AM
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price TargetBenzinga · Jun 15, 2026, 2:05 PM
Kura Oncology And Kyowa Kirin Announce Long-Term Results From The Phase 1/2 KOMET-007 Single-Arm Trial Evaluating Ziftomenib In Combination With Intensive ChemotherapyBenzinga · Jun 11, 2026, 12:09 PM
Kura Oncology And Kyowa Kirin Announce Blood Publication Of Phase 1 Ziftomenib Combination Data Showing 87% ORR In Venetoclax-Naïve R/R NPM1-m AMLBenzinga · Jun 2, 2026, 12:44 PM
Kura Oncology Announces First-In-Human Data From The FIT-001 Clinical Trial Of Darlifarnib In Combination With Adagrasib In Heavily Pretreated Patients With KRAS G12C-Mutated Advanced Solid TumorsBenzinga · May 26, 2026, 10:13 AM
QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga · May 13, 2026, 12:02 PM
8-K filing — Kura Oncology, Inc. (KURA)SEC EDGAR · May 12, 2026, 8:10 PM
Kura Oncology Q1 EPS $(0.83) Beats $(0.94) Estimate, Sales $18.265M Miss $18.513M EstimateBenzinga · May 12, 2026, 8:05 PM